InvestorsObserver
×
News Home

How Does Ionis Pharmaceuticals Inc (IONS) Stock Compare to its Peers?

Wednesday, December 04, 2019 11:12 AM | InvestorsObserver Analysts

Mentioned in this article

How Does Ionis Pharmaceuticals Inc (IONS) Stock Compare to its Peers?

Ionis Pharmaceuticals Inc (IONS) is near the top in its industry group according to InvestorsObserver. IONS gets an overall rating of 39. That means it scores higher than 39 percent of stocks. Ionis Pharmaceuticals Inc gets a 34 rank in the Biotechnology industry. Biotechnology is number 77 out of 148 industries.

Click Here to get the full Stock Score Report on Ionis Pharmaceuticals Inc (IONS) Stock.

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

What's Happening With Ionis Pharmaceuticals Inc Stock Today?

Ionis Pharmaceuticals Inc (IONS) stock is trading at $64.71 as of 11:08 AM on Wednesday, Dec 4, an increase of $0.53, or 0.83% from the previous closing price of $64.18. The stock has traded between $63.81 and $64.80 so far today. Volume today is low. So far 277,503 shares have traded compared to average volume of 975,546 shares.

To see the top 5 stocks in Biotechnology click here.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App